Leave a Reply

Next Post

Blocking FDA approval of abortion pill could stifle innovation in the biopharma industry, experts say

A messy legal fight over the Food and Drug Administration’s approval of the abortion pill mifepristone poses risks to the biopharma industry that go beyond the single drug. If a subsequent decision tosses out the pill’s approval, it could potentially stifle innovation in the sector and deter investments in the […]

You May Like